Results 101 to 110 of about 36,039 (270)

Proactive pharmacogenomics in azathioprine-treated pediatric inflammatory bowel disease at a Chinese tertiary hospital

Frontiers in Pharmacology
BackgroundDespite the emergence of numerous innovative targeted therapies for the management of pediatric inflammatory bowel disease (IBD), azathioprine continues to be a pivotal first-line therapeutic agent.
Cai-Yun Long, Ying Huang
doaj   +1 more source

Chemotherapy resistance and risk stratification in gestational trophoblastic neoplasia: A systematic review and network meta‐analysis

Acta Obstetricia et Gynecologica Scandinavica, EarlyView.
Higher pretreatment β‐hCG, greater tumor burden, higher FIGO stage/score, and choriocarcinoma were associated with higher chemoresistance risk in gestational trophoblastic neoplasia. In exploratory network analyses, etoposide‐containing regimens showed lower predicted chemoresistance.
Ying‐Ying Xue, Xin‐Yue Yang, Fang‐Yu Chen, Hui‐Ting Yang, Chao Zhang, Jin‐Zhu Yan, Shi‐Shi Wu, Long Wang   +7 more
wiley   +1 more source

Inflammatory Bowel Disease Is Associated With an Increased Risk of End‐Stage Renal Disease: A Population‐Based Cohort Study

Alimentary Pharmacology &Therapeutics, EarlyView.
In a retrospective population‐based cohort study using the University of Manitoba IBD Epidemiology Database, persons with IBD have an increased risk of ESRD by nearly 50%, with CD showing greater risk than UC. Bowel surgery, allopurinol use and oral steroid therapy are important predictors, emphasising the necessity of careful renal monitoring in IBD ...
Onuma Sattayalertyanyong, Zoann Nugent, Bryce Barr, Keevin N. Bernstein, Charles N. Bernstein   +4 more
wiley   +1 more source

Prospective Observational Study on the Risk Factors of Chemotherapy-Induced Myelosuppression and Its Management in a Tertiary Care Hospital

Indian Journal of Medical and Paediatric Oncology
Introduction Myelosuppression is a commonly observed dose-limiting side effect of majority of chemotherapeutic drugs, characterized by a decrease in blood cell production.
D. Keziah, M. Bindhiya, M. Jayaprakash, Rodrigues A. Prudence   +3 more
doaj   +1 more source

Janus kinase inhibitors after ruxolitinib failure in myelofibrosis: A systematic review and pooled analysis of phase 3 efficacy and integrated safety across clinical trials and real‐world evidence

British Journal of Haematology, EarlyView.
Summary Ruxolitinib remains first‐line standard of care for symptomatic myelofibrosis, but resistance/intolerance develops in most patients. Three Janus kinase inhibitors (JAKis) have entered the post‐ruxolitinib space via distinct pivotal trials. We systematically searched prospective trials evaluating JAKi in refractory adults with myelofibrosis ...
Andrea Duminuco, Patrick Harrington, Elena Torre, Hillary Catellani, Novella Pugliese, Matteo Pacilli, Annalisa Santisi, Arianna Sbriglione, Giuseppe A. Palumbo   +8 more
wiley   +1 more source

Clinical and laboratory characteristics of patients who developed myelosuppression during low-dose MTX.

, 2016
Clinical and laboratory characteristics of patients who developed myelosuppression during low-dose MTX.
Toshihiko Hidaka (2634763), Toshiro Kawakita (2634769), Yukitaka Ueki (2634766), Hiroyuki Tsuda (52130), Michihiro Hidaka (2634757), Kiyoshi Migita (290200), Shunsuke Mori (487036), Tamami Yoshitama (2634760)   +7 more
core   +1 more source

Plasma glutamic acid predicts myelosuppression and mortality in septic patients using machine learning

Myelosuppression is a common secondary manifestation of sepsis and is associated with increased morbidity and mortality. Recent evidence suggests that amino acid metabolism, particularly that of glutamic acid, may influence hematopoietic function and ...
Fiotti, Nicola, Francesca Spagnol, Di Girolamo, Filippo Giorgio, Biolo, Gianni, Di Bella, Stefano, Alessio Nunnari, Erik Roman Pognuz, Stefano Di Bella, Zerbato, Verena, Filippo Mearelli, Filippo Giorgio Di Girolamo, Nicola Fiotti, Mearelli, Filippo, Pognuz, Erik Roman, Roman Pognuz, Erik, Verena Zerbato, Nunnari, Alessio, Gianni Biolo, Spagnol, Francesca   +18 more
core   +1 more source

Lenalidomide maintenance after initial immunochemotherapy in chronic lymphocytic leukaemia—Final analysis of the international phase III CLL6 RESIDUUM study of the ALLG and FILO groups

British Journal of Haematology, EarlyView.
Summary Most patients treated for chronic lymphocytic leukaemia (CLL) fail to achieve measurable residual disease (MRD) negativity. The role of maintenance with the immunomodulatory drug lenalidomide in these patients is unclear. A randomised multicentre phase III trial (ACTRN12610000060044) was conducted in Australia and France to assess the effect of
Thérèse Aurran‐Schleinitz, Rémi Letestu, Mary Sartor, Stephen Mulligan, Marie C. Béné, Gavin Cull, Dennis Carney, William Renwick, Andrew Grigg, Cecily Forsyth, Gregory Hapgood, Emma Verner, Rosemary Harrup, Pauline Warburton, Kylie Mason, Richard Eek, Wojciech Janowski, Jean Pierre Vilque, Maya Latimer, Laurent Voillat, Sophie De Guibert, Bernard Drenou, Robert Blum, Caroline Dartigeas, Lachlan Hayes, Nicolas Daguindau, Mourad Tiab, Véronique Leblond, Andrew Shearer, Masa Lasica, Pierre Morel, Bohrane Slama, Anne Banos, Annie Brion, Emmanuelle Ferrant, Jessica Michel, Cécile Tomowiak, Edward Morris, Hanlon Sia, Kelly Kratzing, Belinda E. Butcher, Abdelmalek Dahmani, Stephen Robert Larsen, Piers Blombery, Florence Cymbalista, David J. Gottlieb   +45 more
wiley   +1 more source

Alopecia as the first manifestation of azathioprine myelosuppression in a genetically predisposed patient

, 2019
Azathioprine, an analog of mercaptopurine, is used for various inflammatory/autoimmune diseases in diverse fields such as rheumatology, ophthalmology, gastroenterology, and neurology.
Sanjay Jain, Debashish Mishra, Aman Sharma, Shefali Khanna Sharma, Varun Dhir, ShefaliKhanna Sharma   +5 more
core   +1 more source

Triptolide capsule enables proteinuria reduction and renal stabilization in advanced alport syndrome beyond standard therapy

Rheumatology &Autoimmunity, EarlyView.
Zhuo‐ran Song, Na Li, Yang Li, Hong Zhang, Xu‐jie Zhou   +4 more
wiley   +1 more source